Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19
The host immune response, primarily manifested by hypercytokinemia, obviously plays a key role in the development of severe novel coronavirus disease, COVID-19. Currently, numerous therapies aimed at suppressing the hyperinflammatory response and the "cytokine storm" are being investigated...
Main Authors: | M. V. Tolochko, I. N. Leyderman, O. A. Khokhunov, V. A. Mazurok, R. E. Rzheutskya |
---|---|
Format: | Article |
Language: | English |
Published: |
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
2022-02-01
|
Series: | Общая реаниматология |
Subjects: | |
Online Access: | https://www.reanimatology.com/rmt/article/view/2176 |
Similar Items
-
Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-11-01) -
The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01) -
Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series
by: S. O. Salugina, et al.
Published: (2016-02-01) -
Biologic disease-modifying antirheumatic drugs in the treatment of major monogenic autoinflammatory diseases: literature review and clinical observation
by: S. O. Salugina, et al.
Published: (2021-12-01) -
Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01)